| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nanoparticles | 10 | 2013 | 1902 | 0.810 |
Why?
|
| Electronic Health Records | 16 | 2019 | 4440 | 0.710 |
Why?
|
| Molecular Probe Techniques | 2 | 2010 | 119 | 0.670 |
Why?
|
| Medication Therapy Management | 1 | 2019 | 127 | 0.650 |
Why?
|
| Small Molecule Libraries | 2 | 2015 | 721 | 0.650 |
Why?
|
| Natural Language Processing | 7 | 2019 | 1035 | 0.630 |
Why?
|
| Surface Plasmon Resonance | 3 | 2013 | 274 | 0.590 |
Why?
|
| Inflammatory Bowel Diseases | 11 | 2019 | 2410 | 0.470 |
Why?
|
| Cyclooctanes | 1 | 2013 | 32 | 0.470 |
Why?
|
| Algorithms | 11 | 2019 | 13853 | 0.470 |
Why?
|
| Colitis, Ulcerative | 8 | 2019 | 1901 | 0.430 |
Why?
|
| Metformin | 1 | 2019 | 829 | 0.420 |
Why?
|
| Serum Response Factor | 1 | 2012 | 81 | 0.420 |
Why?
|
| Epistasis, Genetic | 1 | 2015 | 365 | 0.420 |
Why?
|
| Crohn Disease | 8 | 2019 | 2301 | 0.410 |
Why?
|
| Cardiovascular Diseases | 11 | 2021 | 15108 | 0.400 |
Why?
|
| Autophagy | 3 | 2013 | 1301 | 0.400 |
Why?
|
| High-Throughput Screening Assays | 5 | 2019 | 944 | 0.380 |
Why?
|
| Biosensing Techniques | 2 | 2013 | 668 | 0.360 |
Why?
|
| Microfluidic Analytical Techniques | 2 | 2013 | 828 | 0.350 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2018 | 997 | 0.340 |
Why?
|
| Adaptive Immunity | 1 | 2013 | 712 | 0.320 |
Why?
|
| Immunologic Factors | 3 | 2015 | 1575 | 0.320 |
Why?
|
| Tetrazoles | 1 | 2013 | 835 | 0.310 |
Why?
|
| Microfilament Proteins | 2 | 2013 | 1152 | 0.310 |
Why?
|
| Molecular Probes | 1 | 2009 | 316 | 0.300 |
Why?
|
| Liver Cirrhosis | 1 | 2017 | 1864 | 0.300 |
Why?
|
| Alleles | 3 | 2015 | 6931 | 0.290 |
Why?
|
| Drug Discovery | 1 | 2015 | 1057 | 0.280 |
Why?
|
| Bone Marrow Cells | 2 | 2011 | 2513 | 0.280 |
Why?
|
| Zebrafish Proteins | 1 | 2012 | 1004 | 0.270 |
Why?
|
| Proteins | 2 | 2012 | 6096 | 0.270 |
Why?
|
| Phenotype | 10 | 2019 | 16331 | 0.270 |
Why?
|
| DNA, Superhelical | 2 | 1997 | 50 | 0.260 |
Why?
|
| DNA, Circular | 2 | 1997 | 96 | 0.260 |
Why?
|
| Materials Testing | 1 | 2008 | 865 | 0.250 |
Why?
|
| Protein Biosynthesis | 1 | 2011 | 2126 | 0.240 |
Why?
|
| Logistic Models | 11 | 2017 | 13403 | 0.230 |
Why?
|
| Stem Cells | 3 | 2011 | 3563 | 0.230 |
Why?
|
| Cyclization | 2 | 2013 | 65 | 0.230 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 5304 | 0.210 |
Why?
|
| Genomics | 2 | 2016 | 5692 | 0.210 |
Why?
|
| Immunity, Innate | 1 | 2013 | 2956 | 0.200 |
Why?
|
| Nucleic Acid Conformation | 2 | 1997 | 914 | 0.200 |
Why?
|
| International Classification of Diseases | 2 | 2018 | 865 | 0.200 |
Why?
|
| Endothelial Cells | 4 | 2014 | 3455 | 0.190 |
Why?
|
| Cholestanol | 1 | 2020 | 4 | 0.190 |
Why?
|
| Lipoproteins, LDL | 2 | 2014 | 628 | 0.190 |
Why?
|
| Vitamin D | 4 | 2015 | 3211 | 0.180 |
Why?
|
| Physicians | 1 | 2018 | 4554 | 0.180 |
Why?
|
| Therapies, Investigational | 1 | 2020 | 111 | 0.180 |
Why?
|
| Cohort Studies | 17 | 2017 | 40450 | 0.170 |
Why?
|
| Structure-Activity Relationship | 5 | 2013 | 3133 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2021 | 11695 | 0.170 |
Why?
|
| Heart | 1 | 2012 | 4462 | 0.170 |
Why?
|
| Gene Expression Regulation | 3 | 2013 | 12071 | 0.160 |
Why?
|
| Oxidoreductases | 1 | 2020 | 424 | 0.160 |
Why?
|
| Th17 Cells | 2 | 2015 | 765 | 0.150 |
Why?
|
| Cell Line | 7 | 2016 | 15994 | 0.150 |
Why?
|
| Digoxin | 3 | 1994 | 250 | 0.150 |
Why?
|
| Humans | 66 | 2021 | 742088 | 0.150 |
Why?
|
| Arthritis, Rheumatoid | 5 | 2015 | 3695 | 0.140 |
Why?
|
| Naphthoquinones | 1 | 2016 | 77 | 0.140 |
Why?
|
| Middle Aged | 28 | 2019 | 213127 | 0.140 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2016 | 4414 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2010 | 3336 | 0.140 |
Why?
|
| Nanotechnology | 2 | 2012 | 709 | 0.130 |
Why?
|
| Risk Factors | 19 | 2019 | 72145 | 0.130 |
Why?
|
| Immunoglobulin Heavy Chains | 3 | 1994 | 659 | 0.130 |
Why?
|
| Electron Transport Complex I | 1 | 2016 | 140 | 0.130 |
Why?
|
| HeLa Cells | 4 | 2014 | 3127 | 0.130 |
Why?
|
| Immunoglobulin Variable Region | 3 | 1993 | 421 | 0.130 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2017 | 213 | 0.130 |
Why?
|
| Diagnostic Imaging | 1 | 2009 | 3507 | 0.130 |
Why?
|
| Kidney Concentrating Ability | 1 | 2014 | 41 | 0.130 |
Why?
|
| Tyrphostins | 1 | 2014 | 67 | 0.120 |
Why?
|
| Databases, Factual | 4 | 2018 | 7716 | 0.120 |
Why?
|
| Male | 36 | 2019 | 349538 | 0.120 |
Why?
|
| Gastrointestinal Agents | 2 | 2016 | 494 | 0.120 |
Why?
|
| Aspartate Aminotransferases | 1 | 2015 | 418 | 0.120 |
Why?
|
| Area Under Curve | 1 | 2018 | 1653 | 0.120 |
Why?
|
| Ligands | 2 | 2012 | 3293 | 0.120 |
Why?
|
| Vitamin D Deficiency | 2 | 2013 | 1331 | 0.120 |
Why?
|
| Aged | 20 | 2018 | 162944 | 0.120 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 1780 | 0.120 |
Why?
|
| Female | 36 | 2019 | 379592 | 0.120 |
Why?
|
| Kinetics | 3 | 2012 | 6474 | 0.120 |
Why?
|
| Cell-Penetrating Peptides | 1 | 2013 | 44 | 0.110 |
Why?
|
| Salmonella Infections, Animal | 1 | 2013 | 65 | 0.110 |
Why?
|
| Narration | 1 | 2015 | 210 | 0.110 |
Why?
|
| Diabetes Mellitus | 4 | 2015 | 5724 | 0.110 |
Why?
|
| Aquaporin 2 | 1 | 2014 | 148 | 0.110 |
Why?
|
| Blood Sedimentation | 1 | 2014 | 231 | 0.110 |
Why?
|
| Alanine Transaminase | 1 | 2015 | 592 | 0.110 |
Why?
|
| Postoperative Hemorrhage | 1 | 2016 | 409 | 0.110 |
Why?
|
| Cycloparaffins | 1 | 2012 | 12 | 0.110 |
Why?
|
| DNA | 4 | 1997 | 7289 | 0.110 |
Why?
|
| Information Storage and Retrieval | 2 | 2015 | 824 | 0.110 |
Why?
|
| Angina Pectoris | 1 | 2016 | 977 | 0.110 |
Why?
|
| Fluorescent Dyes | 2 | 2011 | 1915 | 0.110 |
Why?
|
| Cell-Derived Microparticles | 1 | 2014 | 168 | 0.110 |
Why?
|
| Receptors, LDL | 1 | 2014 | 475 | 0.110 |
Why?
|
| Models, Genetic | 2 | 2014 | 3493 | 0.100 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2014 | 159 | 0.100 |
Why?
|
| Mice, Inbred BALB C | 2 | 2013 | 6382 | 0.100 |
Why?
|
| Expressed Sequence Tags | 1 | 2012 | 255 | 0.100 |
Why?
|
| Risk | 4 | 2017 | 9679 | 0.100 |
Why?
|
| Cyclodextrins | 1 | 2011 | 57 | 0.100 |
Why?
|
| Annexins | 1 | 2011 | 38 | 0.100 |
Why?
|
| Prevalence | 4 | 2016 | 15194 | 0.100 |
Why?
|
| Carrier Proteins | 3 | 2013 | 5019 | 0.100 |
Why?
|
| Anxiety Disorders | 2 | 2013 | 2684 | 0.100 |
Why?
|
| Animals | 25 | 2016 | 168561 | 0.100 |
Why?
|
| Biophysics | 1 | 2012 | 383 | 0.100 |
Why?
|
| Health Services Needs and Demand | 1 | 2019 | 1411 | 0.100 |
Why?
|
| Disease | 1 | 2017 | 681 | 0.100 |
Why?
|
| Cholesterol | 1 | 2020 | 2895 | 0.100 |
Why?
|
| Mice | 15 | 2016 | 81045 | 0.100 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2013 | 494 | 0.100 |
Why?
|
| Carbocyanines | 1 | 2011 | 174 | 0.100 |
Why?
|
| Carotid Arteries | 3 | 2011 | 952 | 0.100 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2015 | 2986 | 0.090 |
Why?
|
| Biomedical Research | 2 | 2017 | 3306 | 0.090 |
Why?
|
| Colorectal Neoplasms | 3 | 2016 | 6754 | 0.090 |
Why?
|
| Parturition | 1 | 2014 | 436 | 0.090 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2010 | 117 | 0.090 |
Why?
|
| Combinatorial Chemistry Techniques | 1 | 2010 | 129 | 0.090 |
Why?
|
| Data Mining | 1 | 2015 | 537 | 0.090 |
Why?
|
| Adamantane | 1 | 2011 | 174 | 0.090 |
Why?
|
| ROC Curve | 1 | 2018 | 3528 | 0.090 |
Why?
|
| Protective Agents | 1 | 2011 | 156 | 0.090 |
Why?
|
| Anticoagulants | 2 | 2016 | 4595 | 0.090 |
Why?
|
| Brachial Artery | 1 | 2011 | 370 | 0.090 |
Why?
|
| Disease Management | 1 | 2020 | 2450 | 0.090 |
Why?
|
| Depressive Disorder | 2 | 2013 | 3748 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 2 | 2019 | 2714 | 0.090 |
Why?
|
| Hospitalization | 3 | 2014 | 10232 | 0.090 |
Why?
|
| Data Collection | 2 | 2016 | 3339 | 0.090 |
Why?
|
| Ferric Compounds | 1 | 2011 | 374 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 2 | 2013 | 4465 | 0.090 |
Why?
|
| Bacteria | 1 | 2020 | 2102 | 0.090 |
Why?
|
| Protein Binding | 3 | 2012 | 9387 | 0.080 |
Why?
|
| Dextrans | 1 | 2011 | 592 | 0.080 |
Why?
|
| Drug Prescriptions | 2 | 2017 | 1636 | 0.080 |
Why?
|
| Neovascularization, Physiologic | 2 | 2011 | 1350 | 0.080 |
Why?
|
| Neurites | 1 | 2011 | 380 | 0.080 |
Why?
|
| Coronary Artery Disease | 3 | 2015 | 6454 | 0.080 |
Why?
|
| Lipoproteins | 1 | 2013 | 876 | 0.080 |
Why?
|
| Th1 Cells | 1 | 2013 | 1056 | 0.080 |
Why?
|
| Diabetes Complications | 1 | 2015 | 1359 | 0.080 |
Why?
|
| Oligonucleotides | 1 | 2011 | 572 | 0.080 |
Why?
|
| Interleukin-1beta | 1 | 2013 | 972 | 0.080 |
Why?
|
| Adult | 21 | 2016 | 213712 | 0.080 |
Why?
|
| Triglycerides | 1 | 2015 | 2450 | 0.080 |
Why?
|
| Adenosine Triphosphate | 2 | 2011 | 2024 | 0.080 |
Why?
|
| Thromboembolism | 1 | 2014 | 983 | 0.080 |
Why?
|
| Endothelium, Vascular | 3 | 2014 | 4455 | 0.080 |
Why?
|
| Nanostructures | 1 | 2012 | 550 | 0.080 |
Why?
|
| Aorta, Abdominal | 1 | 2010 | 645 | 0.080 |
Why?
|
| Biological Products | 1 | 2016 | 856 | 0.080 |
Why?
|
| Zebrafish | 2 | 2012 | 2990 | 0.070 |
Why?
|
| Delivery, Obstetric | 1 | 2014 | 904 | 0.070 |
Why?
|
| Clostridium Infections | 1 | 2014 | 548 | 0.070 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 2866 | 0.070 |
Why?
|
| Cell Membrane | 2 | 2014 | 3744 | 0.070 |
Why?
|
| Staining and Labeling | 1 | 2011 | 1099 | 0.070 |
Why?
|
| Models, Theoretical | 2 | 2017 | 3584 | 0.070 |
Why?
|
| Colonoscopy | 1 | 2014 | 1365 | 0.070 |
Why?
|
| Cadherins | 1 | 2011 | 906 | 0.070 |
Why?
|
| Metal Nanoparticles | 1 | 2010 | 403 | 0.070 |
Why?
|
| Medical Informatics | 1 | 2013 | 742 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2015 | 2455 | 0.070 |
Why?
|
| Cesarean Section | 1 | 2014 | 1363 | 0.070 |
Why?
|
| Dyslipidemias | 1 | 2013 | 848 | 0.070 |
Why?
|
| Multivariate Analysis | 6 | 2015 | 12242 | 0.070 |
Why?
|
| Models, Animal | 1 | 2012 | 2170 | 0.070 |
Why?
|
| Apoptosis | 2 | 2012 | 9715 | 0.070 |
Why?
|
| Aging, Premature | 1 | 2005 | 47 | 0.070 |
Why?
|
| Patients | 1 | 2011 | 892 | 0.060 |
Why?
|
| Rats | 5 | 2014 | 24265 | 0.060 |
Why?
|
| Biological Assay | 1 | 2008 | 652 | 0.060 |
Why?
|
| Leukocytes | 1 | 2013 | 2039 | 0.060 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 2699 | 0.060 |
Why?
|
| Corpus Striatum | 1 | 2011 | 1220 | 0.060 |
Why?
|
| Lamin Type A | 1 | 2005 | 190 | 0.060 |
Why?
|
| Pluripotent Stem Cells | 1 | 2011 | 795 | 0.060 |
Why?
|
| Mice, Knockout | 3 | 2015 | 14554 | 0.060 |
Why?
|
| Risk Assessment | 6 | 2016 | 23320 | 0.060 |
Why?
|
| Huntington Disease | 1 | 2011 | 1111 | 0.060 |
Why?
|
| Homeostasis | 1 | 2015 | 3335 | 0.060 |
Why?
|
| United States | 5 | 2019 | 69693 | 0.060 |
Why?
|
| Molecular Imaging | 1 | 2011 | 831 | 0.060 |
Why?
|
| Venous Thromboembolism | 1 | 2016 | 1668 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 3920 | 0.060 |
Why?
|
| Societies, Medical | 1 | 2016 | 3740 | 0.060 |
Why?
|
| Biopsy | 1 | 2015 | 6756 | 0.060 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2016 | 3239 | 0.060 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 3215 | 0.060 |
Why?
|
| Antibodies | 1 | 2011 | 2459 | 0.060 |
Why?
|
| Hematopoiesis | 1 | 2013 | 2066 | 0.060 |
Why?
|
| Insulin-Secreting Cells | 1 | 2010 | 891 | 0.060 |
Why?
|
| Pedigree | 1 | 2010 | 4646 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2016 | 5310 | 0.050 |
Why?
|
| Genetic Variation | 4 | 2015 | 6540 | 0.050 |
Why?
|
| Lipids | 1 | 2013 | 3302 | 0.050 |
Why?
|
| Intestinal Mucosa | 1 | 2013 | 3038 | 0.050 |
Why?
|
| Monocytes | 1 | 2011 | 2593 | 0.050 |
Why?
|
| Boston | 4 | 2016 | 9305 | 0.050 |
Why?
|
| C-Reactive Protein | 1 | 2014 | 3766 | 0.050 |
Why?
|
| Aortic Coarctation | 1 | 2004 | 281 | 0.050 |
Why?
|
| Mutation | 4 | 2011 | 29717 | 0.050 |
Why?
|
| Fibrin | 2 | 1996 | 506 | 0.050 |
Why?
|
| Calcinosis | 1 | 2010 | 1497 | 0.050 |
Why?
|
| Hemodynamics | 1 | 2011 | 4197 | 0.050 |
Why?
|
| Atherosclerosis | 2 | 2014 | 3428 | 0.050 |
Why?
|
| Sleep | 1 | 2017 | 4604 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2008 | 2713 | 0.050 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2012 | 3617 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 5867 | 0.050 |
Why?
|
| Peripheral Arterial Disease | 1 | 2011 | 1184 | 0.050 |
Why?
|
| Quantitative Trait Loci | 1 | 2008 | 2015 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2008 | 2614 | 0.050 |
Why?
|
| Antigens, CD34 | 2 | 2013 | 657 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2013 | 3381 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2010 | 2867 | 0.050 |
Why?
|
| Heart Ventricles | 1 | 2012 | 3801 | 0.040 |
Why?
|
| Prognosis | 6 | 2016 | 29010 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 2723 | 0.040 |
Why?
|
| Brain Ischemia | 1 | 2013 | 3258 | 0.040 |
Why?
|
| Odds Ratio | 3 | 2017 | 9846 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2009 | 2658 | 0.040 |
Why?
|
| Incidence | 5 | 2015 | 20928 | 0.040 |
Why?
|
| Comorbidity | 4 | 2016 | 10372 | 0.040 |
Why?
|
| Coronary Vessels | 1 | 2010 | 3099 | 0.040 |
Why?
|
| Multiple Sclerosis | 1 | 2013 | 3076 | 0.040 |
Why?
|
| Macrophages | 1 | 2013 | 5655 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2013 | 15530 | 0.040 |
Why?
|
| Glucose | 1 | 2010 | 4391 | 0.040 |
Why?
|
| Follow-Up Studies | 6 | 2016 | 39004 | 0.040 |
Why?
|
| Kidney | 1 | 2014 | 7167 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2021 | 947 | 0.040 |
Why?
|
| Genotype | 4 | 2015 | 12946 | 0.040 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 5019 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2015 | 11470 | 0.040 |
Why?
|
| Carotid Artery Injuries | 1 | 1998 | 96 | 0.040 |
Why?
|
| Cardiac Glycosides | 2 | 2013 | 30 | 0.040 |
Why?
|
| Base Sequence | 5 | 2004 | 12797 | 0.040 |
Why?
|
| Bignoniaceae | 1 | 2016 | 4 | 0.040 |
Why?
|
| Ericaceae | 1 | 2016 | 4 | 0.040 |
Why?
|
| Flow Cytometry | 3 | 2013 | 5975 | 0.040 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1997 | 212 | 0.040 |
Why?
|
| Trazodone | 1 | 2017 | 66 | 0.040 |
Why?
|
| Microscopy, Confocal | 2 | 2014 | 1969 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2013 | 15494 | 0.040 |
Why?
|
| Models, Biological | 1 | 2013 | 9581 | 0.040 |
Why?
|
| Time Factors | 3 | 2014 | 40054 | 0.040 |
Why?
|
| Smegmamorpha | 1 | 2016 | 21 | 0.040 |
Why?
|
| Mutagenesis, Site-Directed | 3 | 2014 | 1723 | 0.040 |
Why?
|
| Metagenomics | 1 | 2020 | 430 | 0.040 |
Why?
|
| Renal Artery Obstruction | 1 | 1998 | 248 | 0.040 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 1997 | 121 | 0.040 |
Why?
|
| Plasminogen Activators | 1 | 1996 | 209 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2011 | 5851 | 0.030 |
Why?
|
| Insulin | 1 | 2010 | 6575 | 0.030 |
Why?
|
| Harmine | 1 | 2015 | 11 | 0.030 |
Why?
|
| Massachusetts | 3 | 2014 | 8662 | 0.030 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 1996 | 337 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2016 | 11690 | 0.030 |
Why?
|
| Vaccinia virus | 1 | 1997 | 349 | 0.030 |
Why?
|
| Myoblasts | 1 | 2016 | 238 | 0.030 |
Why?
|
| Unified Medical Language System | 1 | 2015 | 86 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2019 | 77098 | 0.030 |
Why?
|
| Chi-Square Distribution | 2 | 2014 | 3510 | 0.030 |
Why?
|
| Protein Sorting Signals | 2 | 1993 | 281 | 0.030 |
Why?
|
| Rats, Brattleboro | 1 | 2014 | 41 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 6534 | 0.030 |
Why?
|
| Neoplasms | 2 | 2014 | 21596 | 0.030 |
Why?
|
| Hybridomas | 2 | 1994 | 452 | 0.030 |
Why?
|
| Bayes Theorem | 2 | 2013 | 2303 | 0.030 |
Why?
|
| Vocabulary, Controlled | 1 | 2015 | 170 | 0.030 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 2014 | 118 | 0.030 |
Why?
|
| LLC-PK1 Cells | 1 | 2014 | 132 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 2 | 2014 | 2699 | 0.030 |
Why?
|
| Oxidative Phosphorylation | 1 | 2016 | 480 | 0.030 |
Why?
|
| Feces | 1 | 2020 | 1394 | 0.030 |
Why?
|
| Rectal Fistula | 1 | 2014 | 73 | 0.030 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2014 | 177 | 0.030 |
Why?
|
| Genetic Research | 1 | 2014 | 174 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2016 | 808 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2008 | 13029 | 0.030 |
Why?
|
| DNA Primers | 2 | 2011 | 2892 | 0.030 |
Why?
|
| Computer Security | 1 | 2015 | 263 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 15056 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 2014 | 683 | 0.030 |
Why?
|
| Medical Audit | 1 | 2014 | 467 | 0.030 |
Why?
|
| Molecular Sequence Data | 4 | 1994 | 18112 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 3 | 2011 | 9274 | 0.030 |
Why?
|
| COS Cells | 1 | 2014 | 1160 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2008 | 9144 | 0.030 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2013 | 135 | 0.030 |
Why?
|
| Exocytosis | 1 | 2014 | 353 | 0.030 |
Why?
|
| Thrombosis | 2 | 2016 | 2966 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2012 | 12164 | 0.030 |
Why?
|
| Longitudinal Studies | 3 | 2014 | 13921 | 0.030 |
Why?
|
| Mice, Inbred A | 1 | 1992 | 248 | 0.030 |
Why?
|
| Pyridones | 1 | 2016 | 712 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2009 | 8925 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2012 | 6452 | 0.030 |
Why?
|
| Metabolomics | 1 | 2020 | 1467 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 1887 | 0.030 |
Why?
|
| Immunohistochemistry | 3 | 2014 | 11363 | 0.030 |
Why?
|
| Neurons | 1 | 2011 | 9325 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2013 | 417 | 0.030 |
Why?
|
| Thermodynamics | 1 | 1993 | 594 | 0.030 |
Why?
|
| Glycosylation | 1 | 2014 | 1123 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 1992 | 803 | 0.020 |
Why?
|
| Patient Readmission | 2 | 2016 | 3111 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 2011 | 354 | 0.020 |
Why?
|
| Antibody Affinity | 1 | 1992 | 253 | 0.020 |
Why?
|
| DNA, Single-Stranded | 1 | 1993 | 353 | 0.020 |
Why?
|
| Luminescent Proteins | 1 | 2014 | 853 | 0.020 |
Why?
|
| Salmonella typhimurium | 1 | 2013 | 351 | 0.020 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2014 | 504 | 0.020 |
Why?
|
| Confidentiality | 1 | 2015 | 609 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2016 | 1372 | 0.020 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2010 | 29 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 12344 | 0.020 |
Why?
|
| Sample Size | 1 | 2014 | 844 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1992 | 1086 | 0.020 |
Why?
|
| Cell Line, Tumor | 3 | 2012 | 16665 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 1993 | 625 | 0.020 |
Why?
|
| Linear Models | 2 | 2011 | 5948 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2013 | 15244 | 0.020 |
Why?
|
| Pulsatile Flow | 1 | 2011 | 332 | 0.020 |
Why?
|
| U937 Cells | 1 | 2010 | 268 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2013 | 657 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 2015 | 786 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2013 | 23387 | 0.020 |
Why?
|
| DNA Probes | 1 | 2011 | 560 | 0.020 |
Why?
|
| Patient Care | 1 | 2016 | 639 | 0.020 |
Why?
|
| Life Style | 1 | 2021 | 3824 | 0.020 |
Why?
|
| Microscopy, Atomic Force | 1 | 2010 | 248 | 0.020 |
Why?
|
| Cornea | 1 | 1998 | 1497 | 0.020 |
Why?
|
| Propensity Score | 1 | 2016 | 1771 | 0.020 |
Why?
|
| Magnesium | 1 | 1993 | 813 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2011 | 1374 | 0.020 |
Why?
|
| Gene Knock-In Techniques | 1 | 2011 | 418 | 0.020 |
Why?
|
| Elasticity | 1 | 2011 | 657 | 0.020 |
Why?
|
| Informed Consent | 1 | 2016 | 991 | 0.020 |
Why?
|
| Tissue Plasminogen Activator | 2 | 1996 | 1262 | 0.020 |
Why?
|
| Ultrasonography, Doppler | 1 | 2011 | 458 | 0.020 |
Why?
|
| Cricetulus | 1 | 2011 | 817 | 0.020 |
Why?
|
| Manometry | 1 | 2011 | 444 | 0.020 |
Why?
|
| Dogs | 1 | 2014 | 3910 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2013 | 1583 | 0.020 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2014 | 576 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2011 | 689 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 950 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2013 | 17400 | 0.020 |
Why?
|
| Oxides | 1 | 2010 | 405 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2011 | 544 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 1801 | 0.020 |
Why?
|
| CHO Cells | 1 | 2011 | 1407 | 0.020 |
Why?
|
| Manitoba | 1 | 2008 | 23 | 0.020 |
Why?
|
| Protein Transport | 1 | 2014 | 1988 | 0.020 |
Why?
|
| Methotrexate | 1 | 2015 | 1720 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2013 | 1866 | 0.020 |
Why?
|
| Nanomedicine | 1 | 2011 | 304 | 0.020 |
Why?
|
| Serine Endopeptidases | 1 | 1993 | 1073 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2013 | 1086 | 0.020 |
Why?
|
| Warfarin | 1 | 2016 | 1493 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 1998 | 2633 | 0.020 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2014 | 859 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2011 | 1683 | 0.020 |
Why?
|
| Surface Properties | 1 | 2010 | 1182 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2015 | 1670 | 0.020 |
Why?
|
| Probability | 1 | 1993 | 2502 | 0.020 |
Why?
|
| Disease Progression | 2 | 2014 | 13256 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2013 | 2295 | 0.020 |
Why?
|
| Cricetinae | 1 | 2011 | 2471 | 0.020 |
Why?
|
| Vasodilation | 1 | 2011 | 944 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2014 | 8300 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 1996 | 2161 | 0.020 |
Why?
|
| Models, Statistical | 2 | 2012 | 5100 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 1992 | 1179 | 0.020 |
Why?
|
| Amino Acid Sequence | 3 | 1994 | 13814 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2016 | 1788 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2016 | 1970 | 0.020 |
Why?
|
| Transfection | 1 | 2014 | 5892 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2014 | 21719 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1997 | 2749 | 0.020 |
Why?
|
| Adenine | 1 | 2011 | 936 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 6483 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2015 | 21821 | 0.020 |
Why?
|
| Pyridines | 1 | 2017 | 2818 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2014 | 4211 | 0.020 |
Why?
|
| Young Adult | 3 | 2016 | 56350 | 0.020 |
Why?
|
| Stents | 1 | 2016 | 3276 | 0.020 |
Why?
|
| Reperfusion Injury | 1 | 2011 | 1025 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2011 | 3139 | 0.020 |
Why?
|
| Glucuronidase | 1 | 2005 | 207 | 0.010 |
Why?
|
| Swine | 1 | 2014 | 5934 | 0.010 |
Why?
|
| Gene Expression Profiling | 2 | 2011 | 9410 | 0.010 |
Why?
|
| DNA, Mitochondrial | 1 | 2008 | 814 | 0.010 |
Why?
|
| Diet | 1 | 2021 | 7923 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 1 | 2008 | 1040 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 4751 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2014 | 4024 | 0.010 |
Why?
|
| Length of Stay | 1 | 2016 | 6294 | 0.010 |
Why?
|
| Cytokines | 1 | 1998 | 7317 | 0.010 |
Why?
|
| Membrane Proteins | 2 | 2005 | 7873 | 0.010 |
Why?
|
| Glioblastoma | 1 | 1998 | 3456 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2009 | 62966 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2008 | 1608 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1992 | 6171 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2013 | 2842 | 0.010 |
Why?
|
| Arthritis | 1 | 2008 | 658 | 0.010 |
Why?
|
| Health Status Indicators | 1 | 2008 | 968 | 0.010 |
Why?
|
| Restriction Mapping | 2 | 1993 | 878 | 0.010 |
Why?
|
| Fibrinolytic Agents | 1 | 1991 | 2156 | 0.010 |
Why?
|
| Cross-Sectional Studies | 2 | 2013 | 24913 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2014 | 6191 | 0.010 |
Why?
|
| Adolescent | 3 | 2015 | 85649 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2014 | 3843 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 2013 | 18006 | 0.010 |
Why?
|
| Software | 1 | 2014 | 4434 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2011 | 2896 | 0.010 |
Why?
|
| Survival Rate | 1 | 2014 | 12773 | 0.010 |
Why?
|
| Syndrome | 1 | 2005 | 3248 | 0.010 |
Why?
|
| Sex Factors | 1 | 2013 | 10392 | 0.010 |
Why?
|
| Health Surveys | 1 | 2008 | 4030 | 0.010 |
Why?
|
| Embryonic and Fetal Development | 1 | 1998 | 438 | 0.010 |
Why?
|
| Cloning, Molecular | 2 | 1993 | 4322 | 0.010 |
Why?
|
| Pregnancy | 2 | 2014 | 29087 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 19862 | 0.010 |
Why?
|
| Smoking | 1 | 2013 | 8969 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 9639 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2011 | 19223 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2019 | 53187 | 0.010 |
Why?
|
| Cardenolides | 1 | 1994 | 20 | 0.010 |
Why?
|
| Recombinant Proteins | 2 | 1996 | 6608 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 1998 | 1262 | 0.010 |
Why?
|
| von Willebrand Factor | 1 | 1998 | 668 | 0.010 |
Why?
|
| Stroke | 1 | 2016 | 9963 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2008 | 7770 | 0.010 |
Why?
|
| Angioplasty, Balloon | 1 | 1998 | 653 | 0.010 |
Why?
|
| Hemostasis | 1 | 1996 | 458 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2013 | 12220 | 0.010 |
Why?
|
| Models, Molecular | 2 | 1994 | 5454 | 0.010 |
Why?
|
| Binding Sites, Antibody | 1 | 1993 | 349 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 1993 | 291 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1993 | 708 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1994 | 1094 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 57683 | 0.010 |
Why?
|
| Endopeptidases | 1 | 1993 | 772 | 0.010 |
Why?
|
| Crystallography, X-Ray | 1 | 1994 | 2014 | 0.010 |
Why?
|
| Asthma | 1 | 2008 | 5955 | 0.010 |
Why?
|
| Plasmids | 1 | 1991 | 2305 | 0.000 |
Why?
|
| Protein Conformation | 1 | 1993 | 4013 | 0.000 |
Why?
|
| Binding Sites | 1 | 1994 | 6115 | 0.000 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1991 | 3862 | 0.000 |
Why?
|
| Transcription, Genetic | 1 | 1998 | 7721 | 0.000 |
Why?
|
| Child | 1 | 2008 | 77478 | 0.000 |
Why?
|
| Immunoglobulin G | 1 | 1991 | 4554 | 0.000 |
Why?
|
| Inflammation | 1 | 1998 | 10578 | 0.000 |
Why?
|